vs
Amneal Pharmaceuticals, Inc.（AMRX）与SouthState Bank Corp（SSB）财务数据对比。点击上方公司名可切换其他公司
Amneal Pharmaceuticals, Inc.的季度营收约是SouthState Bank Corp的1.1倍（$722.5M vs $661.7M），SouthState Bank Corp净利率更高（34.1% vs 10.8%，领先23.3%），过去两年SouthState Bank Corp的营收复合增速更高（37.4% vs 1.5%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
SouthState Bank总部位于美国佛罗里达州温特黑文，是银行控股公司SouthState Corporation旗下的银行子公司。截至2025年5月26日，该行已在南卡罗来纳、北卡罗来纳、佐治亚、佛罗里达、阿拉巴马、弗吉尼亚、科罗拉多、得克萨斯八州设有371家营业网点，为当地客户提供各类银行金融服务。
AMRX vs SSB — 直观对比
营收规模更大
AMRX
是对方的1.1倍
$661.7M
净利率更高
SSB
高出23.3%
10.8%
两年增速更快
SSB
近两年复合增速
1.5%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $722.5M | $661.7M |
| 净利润 | $78.0M | $225.8M |
| 毛利率 | 44.3% | — |
| 营业利润率 | 19.6% | 15.1% |
| 净利率 | 10.8% | 34.1% |
| 营收同比 | 3.9% | — |
| 净利润同比 | 410.5% | 153.5% |
| 每股收益（稀释后） | $0.19 | $2.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXSSB
| Q1 26 | $722.5M | $661.7M | ||
| Q4 25 | $814.3M | $581.1M | ||
| Q3 25 | $784.5M | $599.7M | ||
| Q2 25 | $724.5M | $577.9M | ||
| Q1 25 | $695.4M | $544.5M | ||
| Q4 24 | $730.5M | $369.8M | ||
| Q3 24 | $702.5M | $351.5M | ||
| Q2 24 | $701.8M | $350.3M |
净利润AMRXSSB
| Q1 26 | $78.0M | $225.8M | ||
| Q4 25 | $35.1M | $247.7M | ||
| Q3 25 | $2.4M | $246.6M | ||
| Q2 25 | $22.4M | $215.2M | ||
| Q1 25 | $12.2M | $89.1M | ||
| Q4 24 | $-31.1M | $144.2M | ||
| Q3 24 | $-156.0K | $143.2M | ||
| Q2 24 | $6.0M | $132.4M |
毛利率AMRXSSB
| Q1 26 | 44.3% | — | ||
| Q4 25 | 36.5% | — | ||
| Q3 25 | 34.9% | — | ||
| Q2 25 | 39.5% | — | ||
| Q1 25 | 36.8% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 38.4% | — | ||
| Q2 24 | 35.6% | — |
营业利润率AMRXSSB
| Q1 26 | 19.6% | 15.1% | ||
| Q4 25 | 13.8% | 54.3% | ||
| Q3 25 | 9.0% | 53.6% | ||
| Q2 25 | 15.4% | 48.8% | ||
| Q1 25 | 14.4% | 22.3% | ||
| Q4 24 | 10.4% | 50.7% | ||
| Q3 24 | 12.6% | 53.1% | ||
| Q2 24 | 13.6% | 49.3% |
净利率AMRXSSB
| Q1 26 | 10.8% | 34.1% | ||
| Q4 25 | 4.3% | 42.6% | ||
| Q3 25 | 0.3% | 41.1% | ||
| Q2 25 | 3.1% | 37.2% | ||
| Q1 25 | 1.8% | 16.4% | ||
| Q4 24 | -4.3% | 39.0% | ||
| Q3 24 | -0.0% | 40.7% | ||
| Q2 24 | 0.9% | 37.8% |
每股收益（稀释后）AMRXSSB
| Q1 26 | $0.19 | $2.28 | ||
| Q4 25 | $0.10 | $2.47 | ||
| Q3 25 | $0.01 | $2.42 | ||
| Q2 25 | $0.07 | $2.11 | ||
| Q1 25 | $0.04 | $0.87 | ||
| Q4 24 | $-0.10 | $1.88 | ||
| Q3 24 | $0.00 | $1.86 | ||
| Q2 24 | $0.02 | $1.73 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $197.7M | $2.9B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $9.0B |
| 总资产 | $3.5B | $68.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMRXSSB
| Q1 26 | $197.7M | $2.9B | ||
| Q4 25 | $282.0M | — | ||
| Q3 25 | $201.2M | — | ||
| Q2 25 | $71.5M | — | ||
| Q1 25 | $59.2M | — | ||
| Q4 24 | $110.6M | — | ||
| Q3 24 | $74.0M | — | ||
| Q2 24 | $43.8M | — |
总债务AMRXSSB
| Q1 26 | — | — | ||
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — |
股东权益AMRXSSB
| Q1 26 | — | $9.0B | ||
| Q4 25 | $-70.8M | $9.1B | ||
| Q3 25 | $-109.5M | $9.0B | ||
| Q2 25 | $-112.1M | $8.8B | ||
| Q1 25 | $-131.7M | $8.6B | ||
| Q4 24 | $-109.3M | $5.9B | ||
| Q3 24 | $-93.4M | $5.9B | ||
| Q2 24 | $-57.5M | $5.7B |
总资产AMRXSSB
| Q1 26 | $3.5B | $68.0B | ||
| Q4 25 | $3.7B | $67.2B | ||
| Q3 25 | $3.6B | $66.0B | ||
| Q2 25 | $3.4B | $65.9B | ||
| Q1 25 | $3.4B | $65.1B | ||
| Q4 24 | $3.5B | $46.4B | ||
| Q3 24 | $3.5B | $46.1B | ||
| Q2 24 | $3.5B | $45.5B |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
暂无分部数据
SSB
| Net Interest Income | $561.6M | 85% |
| Noninterest Income | $100.1M | 15% |
